Intellia Therapeutics (NTLA) Non-Current Deffered Revenue (2015 - 2025)

Intellia Therapeutics (NTLA) has 11 years of Non-Current Deffered Revenue data on file, last reported at $12.5 million in Q3 2025.

• Quarterly Non-Current Deffered Revenue fell 44.53% year-over-year to $12.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $12.5 million (down 44.53% YoY) and the FY2024 annual result came in at $18.3 million, down 53.01% from the prior year.
• Non-Current Deffered Revenue was little changed at $12.5 million in Q3 2025 per NTLA's latest filing, from $12.5 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $63.5 million in Q4 2021 and bottomed at $12.5 million in Q2 2025.
• The 5-year median for Non-Current Deffered Revenue is $25.7 million (2022), against an average of $29.6 million.
• The widest annual swing landed in 2021, when Non-Current Deffered Revenue soared 251.99%; it then sank 71.99% in 2023.
• Tracing NTLA's Non-Current Deffered Revenue over 5 years: stood at $63.5 million in 2021, then tumbled by 68.6% to $19.9 million in 2022, then soared by 94.93% to $38.9 million in 2023, then plunged by 53.01% to $18.3 million in 2024, then tumbled by 31.32% to $12.5 million in 2025.
• Per Business Quant, the three latest NTLA Non-Current Deffered Revenue figures stand at $12.5 million (Q3 2025), $12.5 million (Q2 2025), and $13.2 million (Q1 2025).

Peer Comparison